Rana R. McKay, MD

In an interview, Rana McKay, MD, discusses findings from the COMRADE trial evaluating olaparib plus radium-223 in prostate cancer presented at the 2025 ASCO Annual Meeting.

Rana R. McKay, MD, discusses the significance of clinical trial data for immunotherapy in muscle-invasive bladder cancer (MIBC) treatment she presented at a Case-Based Roundtable event.

Panelists discuss how unmet needs persist in first-line treatment of metastatic renal cell carcinoma, exploring anticipated advances in tyrosine kinase inhibitor–based therapies and other novel approaches that may address these challenges in the coming years.

Panelists discuss how they balance efficacy outcomes like overall survival and progression-free survival against tolerability and quality of life considerations when making decisions about first-line treatment for metastatic renal cell carcinoma patients.

Panelists discuss how the introduction of adjuvant immunotherapy has influenced their first-line treatment decisions for patients with newly diagnosed metastatic renal cell carcinoma.

Panelists discuss how the management of adverse events differs between tyrosine kinase inhibitor (TKI) monotherapy and immune checkpoint inhibitor plus TKI (ICI+TKI) combinations, including any notable differences in adverse effect profiles among various ICI plus TKI regimens used in treating metastatic renal cell carcinoma.

Panelists discuss how specific disease characteristics, such as tumor burden, metastatic sites, and risk stratification, most strongly influence their decision-making process when choosing between immune checkpoint inhibitor plus tyrosine kinase inhibitor (ICI plus TKI) regimens and dual immune checkpoint inhibitor (ICI plus ICI) combinations for treating metastatic renal cell carcinoma.

Panelists discuss how they approach selecting among various immune checkpoint inhibitor (ICI) plus tyrosine kinase inhibitor (TKI) combinations for first-line treatment of metastatic renal cell carcinoma, considering key factors that influence their decision-making process and drawing insights from recent clinical trials such as CheckMate 9ER, KEYNOTE-426, and CLEAR.

Panelists discuss how the efficacy and safety profiles of various treatment options for intermediate/poor-risk metastatic renal cell carcinoma compare, including cabozantinib monotherapy, nivolumab plus cabozantinib combination, nivolumab plus ipilimumab combination, and other immune checkpoint inhibitor plus tyrosine kinase inhibitor combinations.

Panelists discuss how the first-line treatment landscape for metastatic renal cell carcinoma has evolved in recent years, considering various factors that influence decision-making for newly diagnosed patients.

Matthew Campbell, MD, MS, and Rana McKay, MD, conclude by addressing the remaining unmet needs and persistent treatment challenges faced in managing patients with advanced renal cell carcinoma.

The panelists examine the CheckMate-67T study, which evaluated the efficacy and safety of subcutaneous versus intravenous administration of nivolumab in patients with previously treated advanced or metastatic clear cell renal cell carcinoma.

The panelists compare the adverse event profiles of immunotherapy combination (IO/IO) versus immunotherapy plus tyrosine kinase inhibitor (IO/TKI) regimens, and address the economic implications of managing long-term side effects.

The key opinion leaders share their strategies for selecting systemic therapy, comparing immunotherapy combination (IO/IO) versus immunotherapy plus tyrosine kinase inhibitor (IO/TKI) approaches, for previously untreated patients with advanced renal cell carcinoma.

Medical experts specializing in clear cell renal cell carcinoma examine the concept of treatment-free survival in immunotherapy/tyrosine kinase inhibitor (IO/TKI) regimens, addressing both the advantages and potential drawbacks.

Dr. Campbell evaluates the efficacy and safety results from the 55-month analysis of the CheckMate-9ER trial, and explores the considerations for discontinuing or continuing immunotherapy (IO) in IO/IO versus IO/TKI combination regimens.

The key opinion leaders examine the data from the KEYNOTE-426 trial, focusing on safety and efficacy outcomes along with other pertinent updates.

Matthew Campbell, MD, MS, analyzes the crucial efficacy and safety results from the CLEAR trial's 4-year final analysis, incorporating insights on how these findings influence clinical decision-making for treatment-naïve patients with advanced renal cell carcinoma.

Rana McKay, MD, examines the pivotal efficacy and safety outcomes from the 8-year follow-up of the CheckMate-214 trial in treatment-naïve patients, presented at ASCO GU 2024, and discusses how these findings impact clinical practice.

The key opinion leaders explore extended follow-up results from the CheckMate-214 clinical trial.

Matthew Campbell, MD, MS, and Rana McKay, MD, offer a concise review of existing treatment approaches for clear cell renal cell carcinoma across risk categories, along with considerations for sequencing therapies.

The expert panel concludes with insights on the treatment of patients with renal cell carcinoma who progress following adjuvant therapy.

Experts on renal cell carcinoma discuss how clinical trial data inform treatment decisions, highlighting the negative results from PROSPER, CheckMate 914 Part A, and IMmotion010.

Dr Pal discusses the study design and results of the KEYNOTE-564 trial, and Benjamin Gerendash, MSN, RN, AGACNP-BC, discusses the management of adverse events associated with pembrolizumab.

The panel gives an overview of adjuvant immunotherapy options for patients with renal cell carcinoma.

Sumanta Kumar Pal, MD, FASCO, presents the case of a 48-year-old man with renal cell carcinoma, and Rana R. McKay, MD, discusses how she discusses risk of recurrence with patients.

Following a review of the LITESPARK-005 trial, experts on renal cell carcinoma discuss the potential role of belzutifan in the treatment algorithm.

The panel discusses the lenvatinib plus everolimus regimen for patients with advanced renal cell carcinoma, highlighting clinical trial data on its efficacy and safety profile.

Sumanta Kumar Pal, MD, FASCO, reviews data from the TIVO-3 study investigating tivozanib in patients with advanced renal cell carcinoma, and the panel offers its impressions on the results.

Focusing on VEGF TKIs available for the treatment of patients with metastatic renal cell carcinoma, the panel discusses the goals of therapy in the third-line setting.